SENSEERA

SENSEERA is a promising player in the Health Care sector, founded in 2020 and based in Israel. The company is pioneering advancements in diagnostics and drug development with its AI-driven chromatin liquid biopsy technology.

The foundation of SENSEERA's innovation is its patented GEM (Genomic Expression Maps) Biomarkers, which transform a simple blood draw into intricate, quantitative data about gene expression and regulation. This platform allows for more precise biomarker discovery, early and tissue-agnostic MRD detection, therapy response monitoring, and disease subtyping, significantly outperforming traditional methods.

With a rapidly growing database of over 20,000 disease samples and a collaboration network including leading pharmaceutical and biotech companies, SENSEERA provides critical mechanistic insights. Their technology ensures high sensitivity and specificity, crucial for advancing precision medicine and accelerating drug development worldwide.